US pharma stocks mostly firm after Trump tariffs
View all comments(0)
Shares of major U.S. drugmakers were mostly stable or marginally up after President Donald Trump announced 100% tariffs on branded drugs imported by firms that are not building plants in U.S.
Shares of Abbvie ABBV.N, Merck MRK.N and Eli Lilly LLY.N were up 1% premarket
Shares of Amgen AMGN.O, Pfizer PFE.N, Johnson & Johnson
Most of these companies had been boosting their U.S. manufacturing while the Trump administration weighed hefty tariffs on pharmaceutical imports into the country
Up to last close, LLY down 7.4%, BMY down 23.3% and PFE down 11% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.